{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:42:00Z","timestamp":1791024120769,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.ymgme.2006.01.010","type":"journal-article","created":{"date-parts":[[2006,3,4]],"date-time":"2006-03-04T12:25:00Z","timestamp":1141475100000},"page":"208-215","source":"Crossref","is-referenced-by-count":68,"title":["Lysosomal storage diseases: Natural history and ethical and economic aspects"],"prefix":"10.1016","volume":"88","author":[{"given":"Ernest","family":"Beutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2006.01.010_bib1","unstructured":"National School Lunch Program (NSLP). 2005."},{"key":"10.1016\/j.ymgme.2006.01.010_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0092-8674(78)90102-2","article-title":"Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells","volume":"15","author":"Achord","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2006.01.010_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/bcmd.2000.0310","article-title":"Comparative efficacy of dose regimens in enzyme replacement therapy of type 1 Gaucher disease","volume":"26","author":"Altarescu","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2006.01.010_bib4","unstructured":"G.Anand, How drugs for rare diseases became lifeline for companies, The Wall Street Journal 2005, Dow-Jones, 11-15-0005."},{"key":"10.1016\/j.ymgme.2006.01.010_bib5","unstructured":"G.Anand, Why genzyme can charge so much for Cerezyme, The Wall Street Journal 2005, Dow-Jones, 11-17-2005."},{"key":"10.1016\/j.ymgme.2006.01.010_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00431-003-1363-z","article-title":"Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring","volume":"163","author":"Baldellou","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2006.01.010_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00005792-199511000-00002","article-title":"Gaucher disease","volume":"74","author":"Balicki","year":"1995","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2006.01.010_bib8","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJM199305273282112","article-title":"Treatment of Gaucher\u2019s disease","volume":"328","author":"Barton","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease","volume":"87","author":"Barton","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.01.010_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(77)90123-4","article-title":"Treatment of Gaucher\u2019s disease with liposome-entrapped glucocerebroside: Beta-glucosidase","volume":"2","author":"Belchetz","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.01.010_bib12","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1073\/pnas.90.12.5384","article-title":"Gaucher disease as a paradigm of current issues regarding single gene mutations of humans","volume":"90","author":"Beutler","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.01.010_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(95)91422-6","article-title":"Treatment regimens in Gaucher\u2019s disease","volume":"346","author":"Beutler","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.01.010_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0950-3536(97)80038-8","article-title":"Enzyme replacement therapy for Gaucher disease","volume":"10","author":"Beutler","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.ymgme.2006.01.010_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/bcmd.2000.0311","article-title":"Commentary: dosage-response in the treatment of Gaucher disease by enzyme replacement therapy","volume":"26","author":"Beutler","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2006.01.010_bib16","series-title":"Covalent and Non-covalent Modulation of Protein Function","first-page":"449","article-title":"Enzyme replacement therapy","author":"Beutler","year":"1979"},{"key":"10.1016\/j.ymgme.2006.01.010_bib17","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1073\/pnas.74.10.4620","article-title":"Enzyme replacement therapy in Gaucher\u2019s disease: preliminary clinical trial of a new enzyme preparation","volume":"74","author":"Beutler","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2006.01.010_bib18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJM197704212961618","article-title":"Enzyme replacement with red cells","volume":"296","author":"Beutler","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib19","series-title":"Enzyme Therapy in Genetic Diseases: 2","first-page":"369","article-title":"Replacement therapy in Gaucher\u2019s disease","author":"Beutler","year":"1980"},{"key":"10.1016\/j.ymgme.2006.01.010_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","article-title":"The clinical course of treated and untreated Gaucher disease. A study of 45 patients","volume":"21","author":"Beutler","year":"1995","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2006.01.010_bib21","series-title":"Gaucher Disease: A Century of Delineation and Research","first-page":"669","article-title":"Prospects for enzyme replacement therapy in Gaucher Disease","author":"Brady","year":"1982"},{"key":"10.1016\/j.ymgme.2006.01.010_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM197411072911901","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher\u2019s disease","volume":"291","author":"Brady","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib23","series-title":"Advances in the Treatment of Inborn Errors of Metabolism","first-page":"77","article-title":"Enzyme therapy in Gaucher disease: clinical trials and model system studies","author":"Dale","year":"1982"},{"key":"10.1016\/j.ymgme.2006.01.010_bib24","first-page":"1045","article-title":"From cytases to lysosomes","volume":"23","author":"DeDuve","year":"1964","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ymgme.2006.01.010_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.2000.02177.x","article-title":"Withdrawal of enzyme replacement therapy in Gaucher\u2019s disease","volume":"110","author":"Elstein","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2006.01.010_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1203\/00006450-199205000-00018","article-title":"Enzyme augmentation in moderate to life- threatening Gaucher disease","volume":"31","author":"Fallet","year":"1992","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2006.01.010_bib27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","article-title":"A less costly regimen of alglucerase to treat Gaucher\u2019s disease","volume":"327","author":"Figueroa","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib28","first-page":"792","article-title":"Report of the Spanish Gaucher\u2019s Disease Registry: clinical and genetic characteristics","volume":"85","author":"Giraldo","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2006.01.010_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib30","series-title":"Enzyme Therapy in Genetic Diseases: 2","first-page":"383","article-title":"Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: Beta-glucosidase","author":"Gregoriadis","year":"1980"},{"key":"10.1016\/j.ymgme.2006.01.010_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","article-title":"Cessation of enzyme replacement therapy in Gaucher disease","volume":"4","author":"Grinzaid","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib32","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","article-title":"Individualised low-dose alglucerase therapy for type 1 Gaucher\u2019s disease","volume":"345","author":"Hollak","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.01.010_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/bcmd.1998.0172","article-title":"Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients","volume":"24","author":"Ida","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2006.01.010_bib34","unstructured":"International Collaborative Gaucher Group Registry, Genzyme Therapeutics, Dosage regimens of alglucerase in Gaucher disease: a comparison of the rate and extent of clinical response, ICGG Registry Update (1995) 1\u201311."},{"key":"10.1016\/j.ymgme.2006.01.010_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10729-005-5214-5","article-title":"Engineering the economic value of two pediatric combination vaccines","volume":"8","author":"Jacobson","year":"2005","journal-title":"Health Care Manag. Sci."},{"key":"10.1016\/j.ymgme.2006.01.010_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1005655031239","article-title":"The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations","volume":"23","author":"Maaswinkel-Mooij","year":"2000","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2006.01.010_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","article-title":"Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty-three patients treated for 6 to 24 months","volume":"82","author":"Pastores","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2006.01.010_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.7326\/0003-4819-141-2-200407200-00012","article-title":"Ethics in Practice: managed care and the changing health care environment: medicine as a profession managed care ethics working group statement","volume":"141","author":"Povar","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib39","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2001.19.12.3142","article-title":"The case for a new national program for the development of cancer therapeutics","volume":"19","author":"Schein","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymgme.2006.01.010_bib40","unstructured":"A.Zimran, Personal communication, 2006."},{"key":"10.1016\/j.ymgme.2006.01.010_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90042-6","article-title":"Low-dose enzyme replacement therapy for Gaucher\u2019s disease: effects of age, sex, genotype, and clinical features on response to treatment","volume":"97","author":"Zimran","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymgme.2006.01.010_bib42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher\u2019s disease","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2006.01.010_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671920600028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671920600028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T01:29:06Z","timestamp":1586741346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671920600028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S109671920600028X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2006.01.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}